DexCom (NASDAQ:DXCM) Upgraded to “Strong-Buy” at Baird R W

Baird R W upgraded shares of DexCom (NASDAQ:DXCM) from a hold rating to a strong-buy rating in a research report released on Thursday,Zacks.com reports.

DXCM has been the topic of several other research reports. Oppenheimer reduced their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Sanford C. Bernstein boosted their price target on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $86.00 to $104.00 in a research note on Thursday. Raymond James decreased their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Finally, Leerink Partners dropped their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $99.29.

DexCom Stock Performance

Shares of DexCom stock opened at $84.84 on Thursday. DexCom has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The stock has a market capitalization of $33.14 billion, a price-to-earnings ratio of 50.80, a PEG ratio of 2.00 and a beta of 1.12. The firm has a fifty day moving average of $77.89 and a two-hundred day moving average of $78.41.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On DexCom

Large investors have recently made changes to their positions in the stock. Jennison Associates LLC raised its position in DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after acquiring an additional 6,544,102 shares in the last quarter. Westfield Capital Management Co. LP increased its stake in shares of DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Two Sigma Advisers LP raised its holdings in shares of DexCom by 182.7% in the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock valued at $76,659,000 after purchasing an additional 739,000 shares during the period. Canada Pension Plan Investment Board lifted its stake in DexCom by 189.1% in the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock valued at $75,471,000 after purchasing an additional 435,401 shares during the last quarter. Finally, Intech Investment Management LLC lifted its stake in DexCom by 2,083.0% in the 3rd quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock valued at $25,967,000 after purchasing an additional 369,587 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.